Northstar Select®
Therapy Selection
Northstar Select is a highly sensitive ctDNA liquid biopsy that uses QCTTM technology to guide therapy selection by detecting actionable alterations, even in low tumor fraction samples.
50% Reduction in false negative results
109% More actionable CNVs detected
A purpose-built liquid biopsy
Northstar Select® uncovers treatment opportunities others miss—focused on the genes that matter most for therapy selection.
- Appropriate for all late-stage solid tumor cancers
- 2x - 5x lower LoD than comparator assays2
- Comprehensive 84 gene panel covering:
- 82 genes for single nucleotide variants (SNVs) /indels
- 19 genes for copy number amplifications
- 5 genes for copy number loss
- 9 genes for fusions
- MSI status (microsatellite instability biomarker)
- Results typically within 10 days
The most sensitive liquid biopsy proven to uncover 50%+ more clinically actionable alterations.
Proven to Detect More
Northstar Select was clinically validated in a head-to-head study1 compared with other commercially available liquid biopsy assays. Results demonstrated:
- 51% more SNV/indels detected by Northstar Select
- 109% more copy number alterations
- ~2x fewer false negatives
- Significantly higher detection rates at VAFs below 0.2% where most liquid biopsies miss clinically actionable alterations